Applied Therapeutics, Inc. (APLT) 股票分析

公司概述

Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing a pipeline of novel product candidates targeting validated molecular addresses for indications characterized by high unmet medical needs within the United States. The company functions within the Healthcare sector and specifically the Biotechnology industry, a classification that typically signifies a focus on early-stage research and development rather than established commercial product sales. Its operational scale is defined by a market capitalization of $14.86M, an annual revenue of $1.00M over the trailing twelve months, and a workforce comprising 28 employees. These financial and structural figures indicate that the company is a micro-cap entity with minimal revenue generation relative to its capitalization, suggesting a position typical of pre-commercial biotech firms where valuation is driven largely by potential pipeline assets rather than current cash flow or profit margins.

财务健康

The company reported a revenue of $1.00M for the trailing twelve months, yet recorded a net income of $-18,138,000 and an EBITDA of $-99,611,000. The substantial disparity between the modest revenue figure and the significant negative net income reveals a cost structure dominated by heavy investment in research, development, and operational overhead typical of clinical-stage ventures, where costs far exceed immediate income. Additionally, the free cash flow stands at $-128,157,504, indicating that the company is consuming cash at a rapid pace, which limits its current financial flexibility and necessitates ongoing capital raising to sustain operations. Regarding profitability metrics, the gross margin is 0.0%, the operating margin is -1796.7%, and the profit margin is 0.0%, all of which reflect the non-commercial nature of the business where traditional margin analysis does not yet apply due to the lack of scaled sales. In terms of liquidity and solvency, the company holds $11.95M in cash against $2.50M in debt, while the debt-to-equity ratio is listed as N/A, suggesting a balance sheet that relies heavily on equity financing rather than leverage. The current ratio is 0.96, a figure that indicates the company possesses slightly less current assets than current liabilities, pointing to potential short-term liquidity constraints that must be managed carefully. Finally, the return on equity is -680.5% and the return on assets is -88.3%, metrics that reveal that management is currently utilizing shareholder and asset bases to generate negative returns, a common characteristic during the pre-revenue phase of biotechnology development.

估值评估

The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -0.26, a difference that implies earnings are currently negative and the forward metric is a mathematical artifact of expected future earnings rather than a traditional valuation of current profitability. The price-to-book ratio is -25.75, a negative figure that indicates the market capitalizes the company at a level disconnected from its book value, often seen in speculative assets where the market value is driven by potential rather than tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 14.86 and the EV/EBITDA of -0.05 suggest that investors are pricing the stock based on revenue potential rather than earnings power, highlighting the high risk profile associated with the company's lack of profitability. The 52-week high is $1.50 and the 52-week low is $0.09, meaning the stock has experienced extreme volatility within this range, trading significantly below the high and near the low end of its annual historical performance. The beta value is 2.08, which indicates that the stock price is expected to exhibit price volatility that is more than twice as high as the broader market, reflecting the high sensitivity of biotechnology stocks to clinical trial outcomes and market sentiment.

Growth & Income

The revenue growth year-over-year is 719.7%, while the earnings growth year-over-year is N/A due to continued losses, implying that the company is scaling its top line rapidly but has not yet achieved the profitability required to demonstrate earnings growth. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company reinvests all available resources and any generated earnings back into its research pipeline and operational growth rather than distributing income to shareholders. This profile characterizes the company as a pure growth play with no current income component, where investors accept negative returns and high cash burn in exchange for potential future appreciation if product candidates succeed. Overall, the company presents a high-risk, high-volatility profile with explosive revenue growth potential but no current income generation, making it suitable only for investors seeking exposure to early-stage biotechnology development without reliance on dividends or current profits.